`Case 1:10-cv-00528-GMS Document 151 Filed 02/05/13 Page 1 of 287 PageID #: 3659
`
`IN THE UNITED STATES DISTRICT COURT
`IN AND FOR THE DISTRICT OF DELAWARE
`- - -
`PFIZER INC., PHARMACIA & UPJOHN
`)
`COMPANY, PHARMACIA & UPJOHN
`)
`COMPANY LLC, SUGEN INC., C.P.
`)
`PHARMACEUTICALS INTERNATIONAL
`)
`C.V., PFIZER PHARMACEUTICALS LLC, )
`and PF PRISM C.V.,
`Plaintiffs,
`
`))
`
`))
`
`Civil Action
`
`No. 10-528-GMS
`
`))
`
`))
`
`)
`
`v.
`MYLAN PHARMACEUTICALS INC.,
`Defendant.
`
`- - -
`Wilmington, Delaware
`Thursday, November 29, 2012
`8:30 a.m.
`Trial Day 4
`- - -
`BEFORE: HONORABLE GREGORY M. SLEET, Chief Judge
`APPEARANCES:
`MARYELLEN NOREIKA, ESQ.
`Morris Nichols Arsht & Tunnell, LLP
`-and-
`THOMAS H.L. SELBY, ESQ.,
`WILLIAM E. McDANIELS, ESQ.,
`STANLEY E. FISHER, ESQ.,
`JESSAMYN A. BERNIKER, ESQ.,
`SCOTT DASOVICH, ESQ., and
`JESSICA STOLL, ESQ.
`Williams & Connolly LLP
`(Washington, D.C.)
`
`Counsel for Plaintiffs
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`NOVARTIS EXHIBIT 2024
`Par v. Novartis, IPR 2016-01479
`Page 1 of 4
`
`
`
`779
`Case 1:10-cv-00528-GMS Document 151 Filed 02/05/13 Page 2 of 287 PageID #: 3660
`
`APPEARANCES CONTINUED:
`PHILIP A. ROVNER, ESQ.
`Potter Anderson & Corroon, LLP
`-and-
`DOUGLAS H. CARSTEN, ESQ., and
`JOSH A. MACK, ESQ., and
`BOBBY DELAFIELD, ESQ.
`Wilson Sonsini Goodrich & Rosati
`(San Diego, CA)
`
`Counsel for Defendant
`
`- - -
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`NOVARTIS EXHIBIT 2024
`Par v. Novartis, IPR 2016-01479
`Page 2 of 4
`
`
`
`950
`Case 1:10-cv-00528-GMS Document 151 Filed 02/05/13 Page 173 of 287 PageID #: 3831
`Gering - cross
`reason that the red line is there is because it ignores half
`of the analysis. That's my opinion.
`And you ignored the worldwide revenues in yours.
`Q.
`Correct?
`I did not ignore the worldwide revenues. I did an
`A.
`appropriate analysis of the U.S. market. I looked for
`worldwide data, and it didn't exist, so I couldn't do the
`analysis.
`
`MR. McDANIELS: Thank you, sir.
`THE COURT: Redirect?
`MR. DELAFIELD: I have no redirect.
`THE COURT: Thank you, Doctor. You are excused.
`MR. CARSTEN: Your Honor, Mylan calls, as its
`final witness Dr. Mark J. Ratain.
`MARK J. RATAIN,
`the witness herein, having first been
`duly sworn on oath, was examined and
`testified as follows:
`MR. CARSTEN: Your Honor, may I deliver more
`
`binders?
`
`THE COURT: Yes. Let's take a look.
`MR. CARSTEN: Your Honor, may I just leave the
`previous witness' binders right here?
`DIRECT EXAMINATION
`
`BY MR. CARSTEN:
`
`1 2 3 4 5 6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`NOVARTIS EXHIBIT 2024
`Par v. Novartis, IPR 2016-01479
`Page 3 of 4
`
`
`
`(cid:221)¿›» (cid:239)(cid:230)(cid:239)(cid:240)(cid:243)‰“(cid:243)(cid:240)(cid:240)º(cid:238)Ł(cid:243)(cid:217)(cid:211)˝ (cid:220)–‰«‡»†‹ (cid:239)º(cid:239) (cid:218)•·»… (cid:240)(cid:238)æ(cid:240)ºæ(cid:239)(cid:237) —¿„» (cid:238)(cid:239)Ł –” (cid:238)ŁØ —¿„»(cid:215)(cid:220) (cid:253)(cid:230) (cid:237)ŁØŒ
`
`NOVARTIS EXHIBIT 2024
`Par v. Novartis, IPR 2016-01479
`Page 4 of 4